A1GI34 Stock Overview Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Agilent Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Agilent Technologies Historical stock prices Current Share Price US$416.64 52 Week High US$418.32 52 Week Low US$321.92 Beta 1.06 1 Month Change 3.42% 3 Month Change n/a 1 Year Change 21.57% 3 Year Change -6.64% 5 Year Change n/a Change since IPO 128.55%
Recent News & Updates
Agilent Technologies, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025 Nov 26
Agilent Technologies, Inc. Increases Quarterly Cash Dividend, Payable on January 22, 2025 Nov 21
Agilent Technologies, Inc. Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research Nov 14
Agilent Technologies, Inc. to Report Q4, 2024 Results on Nov 25, 2024 Oct 17
Agilent Technologies, Inc. Announces Quarterly Dividend, Payable on October 23, 2024 Sep 19
Agilent Technologies, Inc. Provides Financial Guidance for the Fourth Quarter of Fiscal 2024 and Revised Financial Guidance for the Full Year of Fiscal 2024 Aug 22 See more updates
Agilent Technologies, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025 Nov 26
Agilent Technologies, Inc. Increases Quarterly Cash Dividend, Payable on January 22, 2025 Nov 21
Agilent Technologies, Inc. Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research Nov 14
Agilent Technologies, Inc. to Report Q4, 2024 Results on Nov 25, 2024 Oct 17
Agilent Technologies, Inc. Announces Quarterly Dividend, Payable on October 23, 2024 Sep 19
Agilent Technologies, Inc. Provides Financial Guidance for the Fourth Quarter of Fiscal 2024 and Revised Financial Guidance for the Full Year of Fiscal 2024 Aug 22
Agilent Technologies, Inc. Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance Aug 16
Agilent Technologies, Inc. Receives FDA Approval for Mage-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy Aug 02
Agilent Technologies, Inc. (NYSE:A) acquired Sigsense Technologies, Inc. Jul 29
Agilent Technologies, Inc. Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit Jul 22
Agilent Technologies, Inc. to Report Q3, 2024 Results on Aug 21, 2024 Jul 17
Agilent Technologies, Inc.(NYSE:A) dropped from Russell 1000 Growth-Defensive Index Jul 03
Agilent Technologies, Inc Appoints Bret Dimarco as Senior Vice President and Chief Legal Officer and Secretary Jul 01
Agilent Technologies, Inc. Is Introducing Two New Products At the 72Nd Asms Conference on Mass Spectrometry and Allied Topics Jun 05 Agilent Technologies, Inc. Provides Financial Guidance for the Third Quarter of Fiscal 2024 and Revises Financial Guidance for the Full Year of Fiscal 2024
Agilent Technologies, Inc. Announces Hans E. Bishop Stepped Down from Board of Directors May 25 Agilent Technologies, Inc. Announces Hans E. Bishop Stepped Down from Board of Directors
Agilent Technologies, Inc. Announces Quarterly Dividend, Payable on July 24, 2024 May 23
Agilent Technologies, Inc. to Report Q2, 2024 Results on May 29, 2024 May 03
Agilent Announces the NovoCyte Opteon, A Cutting-Edge Spectral Flow Cytometry Solution May 01
Agilent Technologies, Inc. Appoints Simon May as President of the Diagnostics and Genomics Group, Effective May 6, 2024 Apr 30
Agilent Technologies, Inc. At AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics Apr 03
Agilent Technologies Inc. Launches New Advanced Dilution System to Increase Lab Efficiency Apr 02
Agilent Technologies, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024 Feb 29 Agilent Technologies, Inc. Announces CEO Changes, effective May 1, 2024
Agilent Technologies, Inc. to Report Q1, 2024 Results on Feb 27, 2024 Jan 26
Agilent Technologies, Inc. Announces New Proteoanalyzer System Jan 16
Agilent Technologies, Inc., Annual General Meeting, Mar 14, 2024 Dec 23 Agilent Makes Strategic Updates to Organizational Structure Dec 21
Agilent Technologies Inc. Announces the Addition of Water Immersion and New Confocal Spinning Disk Technology to the Biotek Cytation C10 Confocal Imaging Reader Dec 04
Agilent Technologies, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year 2024 Nov 21
Agilent Technologies Inc. Increases Quarterly Cash Dividend, Payable on January 24, 2024 Nov 17
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Nov 15
Agilent Technologies, Inc. Announces Resignation of Sam Raha as Senior Vice President of the Company and President of the Diagnostics and Genomics Group Nov 02
Agilent Technologies, Inc. to Report Q4, 2023 Results on Nov 20, 2023 Oct 24
Agilent Technologies, Inc. Announces Quarter Dividend, Payable on October 25, 2023 Sep 21
Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13
Agilent Technologies, Inc. Announces Management Changes Sep 07
Agilent Technologies, Inc. Appoints Philip Binns as President of Life Sciences and Applied Markets Group Sep 06
Agilent Technologies, Inc. Provides Earnings Guidance for the Year 2023 Aug 17
Agilent Technologies, Inc. to Report Q3, 2023 Results on Aug 15, 2023 Jul 22
Agilent Technologies Inc. Announces the Launch of New Gen6 Software for All Agilent BioTek Detection Instruments Jul 11
Agilent Technologies Inc. Introduces New Comprehensive GPC/SEC Solutions At HPLC 2023 Conference Jun 13
Agilent Announces Biotek 406 Fx Washer Dispenser for Technology-Driven Workflow Efficiency Jun 09
Agilent Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ended 2023 May 24
Agilent Technologies, Inc. Announces Cash Dividend, Payable on July 26, 2023 May 18
Agilent Technologies Inc. Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance Feb 10
Agilent Technologies, Inc., Annual General Meeting, Mar 15, 2023 Feb 04
Agilent Technologies, Inc. to Report Q1, 2023 Results on Feb 28, 2023 Jan 31
Agilent Technologies, Inc. (NYSE:A) announces an Equity Buyback for $2,000 million worth of its shares. Jan 10
Agilent Technologies, Inc. (NYSE : A) acquired Avida Biomed Inc. Jan 05
Agilent Technologies, Inc.'s ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer Dec 13
Agilent Technologies, Inc. Provides Revenue Guidance for the First Quarter and Year Full Year 2023 Nov 22
Agilent Technologies Inc. Announces Quarterly Cash Dividend, Payable on January 25, 2023 Nov 17
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0 Nov 15
Agilent Technologies, Inc. to Report Q4, 2022 Results on Nov 21, 2022 Nov 02
Agilent Technologies Inc. Announces Release of its Enhanced 8700 LDIR Chemical Imaging System for Microplastics Analysis Oct 04
Agilent Technologies Inc. Announces Quarterly Cash Dividend, Payable on October 26, 2022 Sep 22
Agilent Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Aug 17
Agilent Technologies, Inc. (NYSE:A) acquired PSS Polymer Standards Service GmbH. Aug 03
Agilent Technologies, Inc. to Report Q3, 2022 Results on Aug 16, 2022 Jul 20 Agilent Technologies, Inc. Announces New Oligonucleotide Analysis Software for Biopharma Research
Agilent Technologies, Inc. Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union Jun 02
Agilent Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Fiscal Year 2022 May 26
Agilent Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Fiscal Year 2022 May 25
Agilent Technologies, Inc. Announces Cash Dividend, Payable on July 27, 2022 May 19
Agilent Technologies Inc. Announces its PD-L1 IHC 22C3 pharmDx, Code SK006, Is Now EU CE-IVD–Marked for Use in Cervical Cancer May 12
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC) Apr 06
Agilent Technologies, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022 Feb 24
Agilent Technologies, Inc. Announces Quarterly Cash Dividend, Payable on April 27, 2022 Feb 16
Agilent Technologies Inc. Highlights Integrated Automation Solutions At SLAS 2022 Feb 05
Agilent Technologies, Inc., Annual General Meeting, Mar 16, 2022 Feb 04
Agilent Announces the Innovative Seahorse XF Pro Analyzer Jan 25
Agilent Technologies, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year 2022 Nov 24
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer Aug 25
Agilent Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021 Aug 19
Agilent Technologies Inc. Completes the InfinityLab Bio LC Portfolio Jun 22
Agilent Announces New SureSelect Human All Exon V8 Jun 03
Agilent Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Year 2021 May 26
Agilent Announces Quarterly Cash Dividend, Payable on July 28, 2021 May 21
Agilent Technologies, Inc. Announces Board Changes Mar 20
Agilent Announces Quarterly Cash Dividend, Payable on April 28, 2021 Mar 18
Agilent Technologies, Inc. Announces the 8697 Headspace Sampler with Integrated Intelligence Mar 16
Agilent Technologies Inc. Appoints Katharine (Kate) Knobil as Its Chief Medical Officer Mar 11
Agilent Technologies Inc. Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection Mar 10
Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Resolution Bioscience, Inc. for approximately $700 million. Mar 04
Agilent Technologies Inc. Announces That the U.S. Food and Drug Administration Approves PD-L1 IHC 22C3 pharmDx assay for Expanded Use in Patients with Non-Small Cell Lung Cancer Feb 24
Agilent Technologies Inc. Announces Launch of Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (Elisa) Kit Feb 19
Agilent Technologies, Inc. Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis Feb 18
Agilent Technologies, Inc., Annual General Meeting, Mar 17, 2021 Feb 05 Shareholder Returns A1GI34 BR Life Sciences BR Market 7D 3.4% 0% 0% 1Y 21.6% 0% 0%
See full shareholder returns
Return vs Market: A1GI34 exceeded the BR Market which returned -11.5% over the past year.
Price Volatility Is A1GI34's price volatile compared to industry and market? A1GI34 volatility A1GI34 Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in BR Market 0% 10% least volatile stocks in BR Market 0%
Stable Share Price: A1GI34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine A1GI34's volatility change over the past year.
About the Company Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Show more Agilent Technologies, Inc. Fundamentals Summary How do Agilent Technologies's earnings and revenue compare to its market cap? A1GI34 fundamental statistics Market cap R$233.39b Earnings (TTM ) R$7.92b Revenue (TTM ) R$40.00b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) A1GI34 income statement (TTM ) Revenue US$6.51b Cost of Revenue US$2.98b Gross Profit US$3.54b Other Expenses US$2.25b Earnings US$1.29b
Last Reported Earnings
Oct 31, 2024
Earnings per share (EPS) 4.52 Gross Margin 54.30% Net Profit Margin 19.80% Debt/Equity Ratio 57.5%
How did A1GI34 perform over the long term?
See historical performance and comparison Dividends
0.7% Current Dividend Yield When do you need to buy A1GI34 by to receive an upcoming dividend? Agilent Technologies dividend dates Ex Dividend Date Dec 27 2024 Dividend Pay Date Jan 28 2025 Days until Ex dividend 6 days Days until Dividend pay date 38 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 17:11 End of Day Share Price 2024/12/17 00:00 Earnings 2024/10/31 Annual Earnings 2024/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Agilent Technologies, Inc. is covered by 43 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Francis Mainwaring Atlantic Equities LLP Catherine Ramsey Schulte Baird Ishan Majumdar Baptista Research
Show 40 more analysts 
